Literature DB >> 3535203

Antimicrobial prophylaxis in urologic surgery.

E H Larsen, T C Gasser, P O Madsen.   

Abstract

Nosocomial urinary tract infections represent approximately 40 per cent of all nosocomial infections, thereby contributing considerably to secondary bacteremia and sepsis and possibly increased mortality. Urethral catheterization is the single most important predisposing factor in the development of urinary tract infection. Patients at increased risk of nosocomial infectious complications are the elderly, malnourished and debilitated, those with diabetes or prosthetic devices, and those on immunosuppressive therapy. About 75 per cent of nosocomial urinary tract infections are attributable to gram-negative bacteria, a disproportionate number of which when compared with community-acquired infections are caused by Proteus, Klebsiella, and Pseudomonas. There is enough evidence in the literature to support the use of prophylaxis in urologic surgery. Antimicrobial prophylaxis reduces the incidence of postoperative urinary tract infection. It does not seem to reduce the incidence of transient perioperative bacteremia but probably prevents the development of sepsis, thereby reducing the number of serious infective complications, the average hospital stay, and the associated total cost of treatment. To achieve adequate urine, blood, and tissue levels of the antimicrobial agent at the time of surgery, the drug should be given preoperatively. A short perioperative course represents sufficient prophylaxis. Regimens with combinations of beta-lactam and aminoglycoside antibiotics or single use of an extended spectrum beta-lactam antibiotic are acceptable for this purpose.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3535203

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  15 in total

Review 1.  Risk factors for sepsis after percutaneous renal stone surgery.

Authors:  Evgeniy I Kreydin; Brian H Eisner
Journal:  Nat Rev Urol       Date:  2013-09-03       Impact factor: 14.432

Review 2.  Percutaneous nephrostomy and antegrade ureteral stenting: technique-indications-complications.

Authors:  Klaus Armin Hausegger; Horst Rupert Portugaller
Journal:  Eur Radiol       Date:  2006-03-18       Impact factor: 5.315

Review 3.  Role of quinolones in surgical prophylaxis.

Authors:  L A Mandell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

4.  Traversing the Renal Pelvis during Percutaneous Nephrostomy Tube Placement ("Kidney Kabob").

Authors:  Mitchell Smith; Paul J Rochon; Charles E Ray
Journal:  Semin Intervent Radiol       Date:  2012-06       Impact factor: 1.513

5.  Prophylactic chemotherapy with fosfomycin trometamol versus placebo during transurethral prostatic resection.

Authors:  L Baert; I Billiet; J Vandepitte
Journal:  Infection       Date:  1990       Impact factor: 3.553

Review 6.  Fluoroquinolones in urinary tract infections. Proper and improper use.

Authors:  K G Naber
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 7.  Prevention and management of infectious complications of percutaneous interventions.

Authors:  Steven Y Huang; Asher Philip; Michael D Richter; Sanjay Gupta; Mark L Lessne; Charles Y Kim
Journal:  Semin Intervent Radiol       Date:  2015-06       Impact factor: 1.513

8.  Concentrations of ceftriaxone (1,000 milligrams intravenously) in abdominal tissues during open prostatectomy.

Authors:  C Martin; X Viviand; A Cottin; V Savelli; C Brousse; E Ragni; C Richaud; M N Mallet
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

9.  Multibacterial growth from a surgical renal stone culture: a case report and literature review.

Authors:  Patrick W Mufarrij; Jessica N Lange; Dean G Assimos; Majid Mirzazadeh; Ross P Holmes
Journal:  Rev Urol       Date:  2012

10.  Influence of urological irrigation fluids on urothelial bacterial adherence.

Authors:  T C Gasser; P O Madsen
Journal:  Urol Res       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.